The underlying factors driving myelofibrosis
might surprise you.
The impact of driver mutations on the JAK-STAT pathway is well known, but there is more to uncover about myelofibrosis (MF).1 Emerging data have helped identify and validate other somatic mutations, disease phenotypes, and molecular pathways that can impact disease progression. These discoveries help researchers understand why MF may be driven by the JAK-STAT pathway in some patients—but not in all patients.1,2
The underlying factors driving myelofibrosis
might surprise you.
The impact of driver mutations on the JAK-STAT pathway is well known, but there is more to uncover about myelofibrosis (MF).1 Emerging data have helped identify and validate other somatic mutations, disease phenotypes, and molecular pathways that can impact disease progression. These discoveries help researchers understand why MF may be driven by the JAK-STAT pathway in some patients—but not in all patients.1,2
Primary MF and secondary MF are different at their core.1,2
Primary and secondary MF have certain similarities, but their differences may reveal more about the complexity and severity of primary MF. Taking a closer look at the unique molecular profile of primary MF—including the various driver and high-risk mutations—may provide more insight about chronic inflammation, cytopenias, and the clinical challenges of each patient's case.
Phenotypes have revealed another layer of heterogeneity in MF.2
Cytopenias are just one of several factors that have been shown to define distinct disease phenotypes, each with potentially significant clinical challenges. As researchers investigate these phenotypes and how cytopenias may change over time—whether due to disease progression and/or disease management—they discover what the heterogeneity of MF may reveal about unmet patient needs.
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
PATHWAY
There may be more to MF
than the JAK‑STAT pathway.3,4
As research continues to uncover more about the complexity and evolving biology of MF, it reveals the need to look more closely at emerging pathways beyond JAK-STAT. With each pathway discovered, researchers learn more about the need to focus disease management on what may be driving disease progression in each patient.
- 1. Vainchenker W and Kralovics R. Blood. 2017;129(6):667-679.
- 2. Marcellino BK, et al. Clin Lymphoma Myeloma Leuk. 2020;20(7):415-421.
- 3. Singer JW, et al. Oncotarget. 2018;9(70):33416-33439.
- 4. Naymagon L and Mascarenhas J. HemaSphere. 2017;1(1):e1.